Monitoring Platelet Function During Continuous Hemodialysis

March 2, 2017 updated by: Saskia Wand, Goethe University

Changes in Platelet Function During Continuous Veno-venous Hemodialysis Using the Multiplate Device

Aim of the study is a description of changes in platelet function during continuous veno-venous hemodialysis or hemofiltration in patients on an intensive care unit using the Multiplate system.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Germany
    • Hessen
      • Frankfurt, Hessen, Germany, 60590
        • Johann Wolfgang Goethe-University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients in an intensive care unit with the need for a renal replacement therapy-

Description

Inclusion Criteria:

  • Need for a continuous renal replacement therapy
  • Platelet Count >100.000/nl

Exclusion Criteria:

  • Pregnancy
  • Age <18 years
  • Renal replacement therapy within the 7 days prior to enrollment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Dialysis
Platelet function will be documented during the first 48 hours of veno-venous hemofiltration using the Multiplate system.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ASPItest
Time Frame: Baseline, 6, 12, 24 and 48 hours
Area under the aggregation curve (AUC) after platelet stimulation with arachidonic acid at baseline and 6, 12, 24 and 48 hours after the start of the continuous hemofiltration.
Baseline, 6, 12, 24 and 48 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ADPtest
Time Frame: Baseline, 6, 12, 24 and 48 hours
Area under the aggregation curve (AUC) after platelet stimulation with adenosine diphosphate at baseline and 6, 12, 24 and 48 hours after the start of the continuous hemofiltration.
Baseline, 6, 12, 24 and 48 hours
TRAPtest
Time Frame: Baseline, 6, 12, 24, 48 hours
Area under the aggregation curve (AUC) after platelet stimulation with thrombin-receptor-activating peptide 6 (TRAP-6) at baseline and 6, 12, 24 and 48 hours after the start of the continuous hemofiltration.
Baseline, 6, 12, 24, 48 hours
CT-INTEM
Time Frame: Baseline, 6, 12, 24 and 48 hours
Clotting time (CT) in the intrinsically activated rotational thrombelastometry (ROTEM) recorded in seconds at baseline and 6, 12, 24 and 48 hours after the start of continuous veno-venous hemofiltration.
Baseline, 6, 12, 24 and 48 hours
MCF-INTEM
Time Frame: Baseline, 6, 12, 24 and 48hours
Maximum clot firmness (MCF) in the intrinsically activated rotational thrombelastometry (ROTEM) recorded in millimeters at baseline and 6, 12, 24 and 48 hours after the start of continuous veno-venous hemofiltration.
Baseline, 6, 12, 24 and 48hours

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Gender
Time Frame: Baseline
Baseline
Age
Time Frame: Baseline
Age of the patient at the point of enrollment
Baseline
Height
Time Frame: Baseline
Height of the patient measured in centimeters.
Baseline
Weight
Time Frame: Baseline
Weight of the patient measured in kilograms.
Baseline
ASA-Classification
Time Frame: Baseline
The ASA-Classification will be determined preoperatively.
Baseline
Antiaggregatory Premedication
Time Frame: Baseline
Antiaggregatory medication taken prior to enrollment wil be recorded in the categories aspirin, clopidogrel, ticagrelor, cumarins and others.
Baseline
Dialysis filter
Time Frame: Basline
The brand of filter used for the hemofiltration or hemodialysis will be registered.
Basline
Anticoagulation for hemofiltration
Time Frame: Baseline
The anticoagulation used for hemofiltration will be recorded in the categories heparin and calcium citrate.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Goethe University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2012

Primary Completion (Actual)

August 1, 2013

Study Completion (Actual)

August 1, 2013

Study Registration Dates

First Submitted

April 16, 2013

First Submitted That Met QC Criteria

April 18, 2013

First Posted (Estimate)

April 23, 2013

Study Record Updates

Last Update Posted (Actual)

March 3, 2017

Last Update Submitted That Met QC Criteria

March 2, 2017

Last Verified

March 1, 2017

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • CVVH-Multiplate

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Platelet Function

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe